Lack of Cyclooxygenase-2 Activity in HT-29 Human Colorectal Carcinoma Cells

doi:10.1006/excr.2000.4863

Experimental Cell Research

Volume 256, Issue 2, 1 May 2000, Pages 563-570

https://doi.org/10.1006/excr.2000.4863 Get rights and content

Abstract

Induction of cyclooxygenase-2 (COX-2) is an early event in the sequence of polyp formation to colon carcinogenesis. COX-2 is at elevated levels in human colorectal cancers and in tumors and polyps of mouse models of colorectal cancer. Mutation of the adenomatous polyposis coli (APC) gene is the initial event leading to colorectal cancer. Colorectal cells in culture which express mutant APC are often used to examine the association of COX-2 expression and apoptosis. The expression of full-length APC in HT-29 cells, a human colorectal carcinoma cell line which normally expresses truncated APC and highly expresses COX-2, inhibits cell growth through increased apoptosis and results in a down-regulation of COX-2 protein. In this report, we examine whether down-regulation of COX-2 is directly linked to the increase in apoptosis observed in these HT-29-APC cells. We present evidence that COX-2 and apoptosis are not linked since COX-2, although expressed, is catalytically inactive. Interestingly, the COX-2 cloned from HT-29 cells is catalytically active when transfected into HCT-116 cells, a colorectal cell line which normally does not express COX-2, but is not active in the HT-29 cell line itself.

References (38)

W.L. Smith et al.
Prostaglandin endoperoxide H synthases-1 and -2
Adv. Immunol.
(1996)
H.R. Herschman
Prostaglandin synthase 2
Biochim. Biophys. Acta
(1996)
B.S. Fletcher et al.
Structure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase
J. Biol. Chem.
(1992)
B.M. Jaffe
Prostaglandins and cancer: An update
Prostaglandins
(1974)
R.N. DuBois et al.
Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors
Gastroenterology
(1996)
C.W. Williams et al.
Elevated cyclooxygenase-2 levels in Min mouse adenomas
Gastroenterology
(1996)
M. Oshima et al.
Suppression of intestinal polyposis in APC^Δ716 knockout mice by inhibition of cyclooxygenase 2
Cell
(1996)
M. Tsujii et al.
Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
Cell
(1995)
D.C. Henke et al.
Analysis of leukotrienes, prostaglandins, and other oxygenated metabolites of arachidonic acid by high-performance liquid chromatography
Anal. Biochem.
(1984)
H. Kamitani et al.
Expression of 15-lipoxygenase by human colorectal carcinoma Caco-2 cells during apoptosis and cell differentiation
J. Biol. Chem.
(1998)

R. Hanif et al.

Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway

Biochem. Pharmacol.

(1996)

J. Parker et al.

Prostaglandin H synthase expression is variable in human colorectal adenocarcinoma cell lines

Exp. Cell Res.

(1997)

E.A. Meade et al.

Proxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells

J. Biol. Chem.

(1999)

J.M. Lehmann et al.

Proxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs

J. Biol. Chem.

(1997)

B.M. Spiegelman et al.

Adipogenesis and obesity: Rounding out the big picture

Cell

(1996)

T.C. He et al.

PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs

Cell

(1999)

V.J. Murphy et al.

Cyclooxygnease-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines

Cancer Lett.

(1998)

H. Sano et al.

Expression of cyclooxygenase-1 and -2 in human colorectal cancer

Cancer Res.

(1995)

Cited by (58)

Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity
2023, European Journal of Medicinal Chemistry
Several studies have indicated the potential therapeutic outcomes of combining selective COX-2 inhibitors with tubulin-targeting anticancer agents. In the current study, a novel series of thiazolidin-4-one-based derivatives (7a–q) was designed by merging the pharmacophoric features of some COXs inhibitors and tubulin polymerization inhibitors. Compounds 7a–q were synthesized and evaluated for their cytotoxic activity against MCF7, HT29, and A2780 cancer cell lines (IC₅₀ = 0.02–17.02 μM). The cytotoxicity of 7a–q was also assessed against normal MRC5 cells (IC₅₀ = 0.47–13.46 μM). Compounds 7c, 7i, and 7j, the most active in the MTT assay, significantly reduced the number of HT29 colonies compared to the control. Compounds 7c, 7i, and 7j also induced significant decreases in the tumor volumes and masses in Ehrlich solid carcinoma-bearing mice compared to the control. The three compounds also exhibited significant anti-HT29 migration activity in the wound-healing assay. They have also induced cell cycle arrest in HT29 cells at the S and G₂/M phases. In addition, they induced significant increases in both early and late apoptotic events in HT29 cells compared to the control, where 7j showed the highest effect. On the other hand, compound 7j (1 μM) displayed weak inhibitory activity against tubulin polymerization compared to colchicine (3 μM). On the other hand, compounds 7a–q inhibited the activity of COX-2 (IC₅₀ = 0.42–29.11 μM) compared to celecoxib (IC₅₀ = 0.86 μM). In addition, 7c, 7i, and 7j showed moderate inhibition of inflammation in rats compared to indomethacin, with better GIT safety profiles. Molecular docking analysis revealed that 7c, 7i, and 7j have higher binding free energies towards COX-2 than COX-1. These above results suggested that 7j could serve as a potential anticancer drug candidate.
Metalcarbonyl complexes of acetylsalicylic acid as neo-anticancer agents
2010, European Journal of Medicinal Chemistry
Citation Excerpt :
Despite the success of cisplatin and closely related platinum agents in tumor therapy [1,2], there is an increasing interest in new metal-based drugs for the second line therapy of platinum resistant tumors, e.g. the mammary carcinoma using carrier ligands [3–8].
[(Prop-2-ynyl)-2-acetoxybenzoate]dicobalthexacarbonyl (Co-ASS), a derivative of the nonsteroidal anti-inflammatory drug aspirin^® (ASS), demonstrated high cytotoxic potential against various tumor cells. The [acetylene]Co₂(CO)₆ cluster strongly increased the biological effects compared to aspirin^®. In this study we evaluated the use of [cyclopentadienyl]metalcarbonyl as cytotoxic moiety with a broader series of metals: molybdenum, manganese, cobalt and rhodium. All compounds were tested for cytotoxicity against breast (MCF-7, MDA-MB-231) and colon cancer (HT-29) cell lines. Their COX-1 and COX-2 inhibitory effects were evaluated at isolated isoenzymes. Additionally, the influence on the level of the major COX metabolite prostaglandin E₂ (PGE₂) was quantified in MDA-MB-231 breast cancer cells. Whereas the pure ligands or ASS did not show any cytotoxic effect, all metal complexes inhibited the tumor cell growth. The inhibitory effects at COX-1 and COX-2 enzymes were low. Only the Prop-Cp-ASS-Rh complex (10 μM) caused an important inhibition of COX-1 by 60% and COX-2 by 30%. ASS showed at the same concentration only a marginal repression of COX-1 activity (30%) and no effect on COX-2.
4-Thiazolidinone - A biologically active scaffold
2008, European Journal of Medicinal Chemistry
Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer
2006, European Journal of Pharmaceutical Sciences
The purpose of this study was to develop a biodegradable drug platform composed of chitosan and guar gum and to explore the possibility of using it for local adjuvant or neoadjuvant therapy of colorectal cancer. Celecoxib (Cx), a chemopreventative drug for familial adenomatous polyposis (FAP) and under trial for reducing post surgical colorectal malignancies, was selected as a model drug for this topical system because of the contraindications that are associated with its systemic administration.
Films made of chitosan (Ct) and guar gum (GG) were prepared, characterized for equilibrium swelling, mucoadhesion, in vitro and in vivo degradation and loaded with Cx. Short term dosing studies in vitro were performed in the HT-29 colon carcinoma cell line that was incubated with Cx using the MTT test to assess IC50. The impact of a single high dose was evaluated and compared with a repeating low-dose regimen. In vivo dosing experiments with Cx were performed in the perfused intestine of the anaesthetized rat. Measuring tissue LDH assessed epithelium injury.
Mechanical, mucoadhesion and in vitro degradation of the polysaccharide films were dictated by manipulating the ratios of Ct and GG. The addition of rat cecal contents to the dissolution medium increased the total Cx released from those films containing high amounts of GG. MTT reduction, a measure of cell proliferation, diminished as a function of increasing drug concentration and exposure time in the HT-29 cell line studies.
Local high concentrations of Cx were shown to impede the proliferation of cancer cells directly, while chemoprevention has been demonstrated with low Cx doses. Healthy cells were shown to be sensitive to high Cx doses. Maximum therapeutic efficiency in the context of minimal healthy tissue exposure would thus be predicted utilizing a local delivery system such as the proposed adhesive, biodegradable polysaccharide composites.
In Vitro Cytostatic Effect on Tumor Cells by Carborane-Based Dual Cyclooxygenase-2 and 5-Lipoxygenase Inhibitors
2023, Advanced Therapeutics
Mechanisms of colorectal cancer prevention by aspirin—a literature review and perspective on the role of cox-dependent and-independent pathways
2020, International Journal of Molecular Sciences

View all citing articles on Scopus

¹: To whom correspondence and reprint requests should be addressed at NIEHS, P.O. Box 12233, Research Triangle Park, NC 27709. Fax: (919) 541-0146. E-mail: [email protected].

View full text

Regular ArticleLack of Cyclooxygenase-2 Activity in HT-29 Human Colorectal Carcinoma Cells

Abstract

Adv. Immunol.

Biochim. Biophys. Acta

J. Biol. Chem.

Prostaglandins

Gastroenterology

Gastroenterology

Cell

Cell

Anal. Biochem.

J. Biol. Chem.

Biochem. Pharmacol.

Exp. Cell Res.

J. Biol. Chem.

J. Biol. Chem.

Cell

Cell

Cancer Lett.

Expression of cyclooxygenase-1 and -2 in human colorectal cancer

Cancer Res.

Regular Article
Lack of Cyclooxygenase-2 Activity in HT-29 Human Colorectal Carcinoma Cells